Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Brigatinib vs Crizotinib in ALK-positive NSCLC
2015-003447-19Phase 3Unknown
- Sponsor
- Takeda
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of brigatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-003447-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003447-19.